[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lantern Pharma Inc (LTRN)

Lantern Pharma Inc (LTRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,741
  • Shares Outstanding, K 11,305
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,120 K
  • EBIT $ -18 M
  • EBITDA $ -18 M
  • 60-Month Beta 2.10
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.49

Options Overview Details

View History
  • Implied Volatility 525.56% (+0.22%)
  • Historical Volatility 212.97%
  • IV Percentile 83%
  • IV Rank 57.40%
  • IV High 857.88% on 02/18/26
  • IV Low 77.80% on 01/30/26
  • Expected Move (DTE 5) 0.67 (31.98%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 39
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 359
  • Open Int (30-Day) 403
  • Expected Range 1.43 to 2.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.54
  • Growth Rate Est. (year over year) +185,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.85 +13.51%
on 04/09/26
2.82 -25.53%
on 04/21/26
+0.16 (+8.25%)
since 04/08/26
3-Month
1.11 +89.19%
on 03/27/26
3.09 -32.04%
on 02/25/26
-0.54 (-20.45%)
since 02/06/26
52-Week
1.11 +89.19%
on 03/27/26
5.74 -63.44%
on 08/06/25
-1.76 (-45.60%)
since 05/08/25

Most Recent Stories

More News
Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™

Planned additions are designed to expand and enhance withZeta.ai’s capabilities, including: real-time, multi-omic computational analyses; simultaneous, highly parallel multi-agentic reasoning, and enterprise-grade...

LTRN : 2.10 (+2.94%)
Lantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally

360-Degree Small-Molecule Developability Profiling from a Single SMILES String in Seconds by characterizing and calculating 99 critical molecular features ...

LTRN : 2.10 (+2.94%)
New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global

Sponsored Programming Supported by Commercials from Medicus Pharma (NASDAQ:MDCX), IGC Pharma (NYSE American:IGC), Roadzen (NASDAQ:RDZN), and Lantern Pharma (NASDAQ:LTRN)

RDZN : 1.8000 (-3.74%)
IGC : 0.3110 (-2.54%)
LTRN : 2.10 (+2.94%)
NRXP : 3.08 (+0.65%)
MDCX : 0.3350 (+6.69%)
CISO : 0.2982 (+6.12%)
Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut

CEO Panna Sharma to Lead Live, Unscripted Platform Walkthrough in Two Interactive Sessions on April 30, 2026 — Open to Investors, Researchers, and the Global Biomedical Community Registration...

LTRN : 2.10 (+2.94%)
CORRECTION: Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers

This version updates the headline which had a misspelling

LTRN : 2.10 (+2.94%)
Join Lantern Pharma on April 30 for the First Public Demonstration of with Zeta.ai - A Platform to Conquer Rare Cancers

CEO Panna Sharma to Lead Live, Unscripted Platform Walkthrough in Two Interactive Sessions on April 30, 2026 - Open to Investors, Researchers, and the Global Biomedical Community

LTRN : 2.10 (+2.94%)
Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity

Lantern Pharma Schedules Type C Meeting with the FDA to Advance HARMONIC™ Protocol Amendments Targeting This High-Need Population, Reflecting LP-300’s Novel Mechanism of Action and the Rapidly Evolving...

LTRN : 2.10 (+2.94%)
RedChip's Biotech Investor Conference Replays Now Available

ORLANDO, FL / ACCESS Newswire / April 20, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced that on-demand replays...

NXL : 0.3524 (+2.44%)
BIVI : 1.4700 (-4.55%)
SXTP : 1.5400 (-2.53%)
BFRG : 0.6600 (+1.59%)
LTRN : 2.10 (+2.94%)
Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22

Platform Now Available with Introductory, Academic, & Commercial Subscription Tiers Live Debut at Nasdaq MarketSite, New York City — April 16, 2026,...

LTRN : 2.10 (+2.94%)
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026

Briefing to Feature a Live Walkthrough, Demonstration of Key Features, The Market Opportunity & Industry Need, Competitive Positioning, and Platform Monetization Strategy

LTRN : 2.10 (+2.94%)

Business Summary

Lantern Pharma Inc.is a biotechnology company. It develops medicines for multi-drug treatment resistance cancers focusing on prostate and ovarian cancers. The company's drug candidate consist LP-100, LP-300 and LP-184 which are in clinical stage. Lantern Pharma Inc.is based in Dallas, Texas.

See More

Key Turning Points

3rd Resistance Point 2.26
2nd Resistance Point 2.20
1st Resistance Point 2.15
Last Price 2.10
1st Support Level 2.04
2nd Support Level 1.99
3rd Support Level 1.94

See More

52-Week High 5.74
Fibonacci 61.8% 3.97
Fibonacci 50% 3.43
Fibonacci 38.2% 2.88
Last Price 2.10
52-Week Low 1.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.